Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

NCT02183610 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: [14C] BI 1356 as oral (p.o.) solution
DRUG: [14C] BI 1356 solution for i.v. infusion

Sponsor

Boehringer Ingelheim